Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Investment Securities (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Gains from Investment Securities data on record, last reported at $12.3 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 4301.43% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $12.5 million, up 2349.22%, while the annual FY2025 figure was $60.0 million, 7373.31% up from the prior year.
  • Gains from Investment Securities reached $12.3 million in Q4 2025 per COLL's latest filing, up from -$19000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $12.3 million in Q4 2025 and bottomed at -$19000.0 in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $2.1 million, with a median of $438000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: crashed 97.62% in 2024, then skyrocketed 4301.43% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $4.1 million in 2021, then plummeted by 91.2% to $363000.0 in 2022, then crashed by 35.81% to $233000.0 in 2023, then rose by 19.74% to $279000.0 in 2024, then surged by 4301.43% to $12.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $12.3 million in Q4 2025, -$19000.0 in Q3 2025, and $14949.0 in Q2 2025.